
Sinners finally comes home to Clarksdale: a three-day festival premieres the film in its hometown
In April, the director Ryan Coogler released Sinners, a thriller about two brothers in the 1930s who return home to Clarksdale, Mississippi, to open a juke joint. Less than a month after the film was released, Sinners made over $200m in the US and Canada, something no original film has done in almost a decade.
But residents in Clarksdale, a town with about 14,000 people, the majority of whom are Black, had no way to see themselves on screen in their community. There are no active movie theaters in or near the town.
Tyler Yarbrough, a Clarksdale native and community leader, published an open letter on behalf of 'an intergenerational group of organizations, creatives, entrepreneurs, farmers, and community leaders' inviting Coogler and the Sinners cast to town.
'We are extending an open invitation to you, the cast, and the creative team behind Sinners to visit Clarksdale, to walk the streets your vision reimagined, to meet the people whose real stories echo through every frame, and to experience firsthand the living, breathing legacy that inspired your work and the people who are sustaining and reimagining its future,' Yarbrough wrote.
'We would also be honored to collaborate with you to host a public screening and celebration here in Clarksdale. A homecoming not just for the film, but for the history, culture, and future that continue to define our city and to connect Mississippi creatives with you and your work.'
The letter quickly went viral after Capital B, a Black-led non-profit news organization, reported about it and it was picked up both by other news outlets and on social media.
'We're also hoping for them to see the people who are actually doing some badass shit right now when it comes to the juke joints, keeping them alive, when it comes to some of the farmers who are rethinking farming, from cotton to produce,' Yarbrough told the Guardian in early May. 'The blues is the foundation of all American music and American culture. There's so much power in that that originates here. As we think about our national story, our community story, I do think Clarksdale and the [Mississippi] delta, specifically, is going to be a part of this retelling of America to this connecting all Black people in this country back to this ancestral land too.'
Coogler and Warner Bros heard and answered the call, and on 29 May, people in Clarksdale were finally able to see themselves in their own community.
As a part of Clarksdale Cultural Capital, a three-day festival sponsored by Warner Bros and others, residents of Clarksdale have multiple free opportunities to see the movie in their home town.
Coogler; his wife, a producer and co-founder of Proximity Media, Zinzi Coogler; Ludwig Göransson, the film's composer; Sev Ohanian, another producer and co-founder of Proximity Media; and executive music producer Serena Göransson attended and introduced the 29 May morning screening, which was held in the Clarksdale civic auditorium.
Both Cooglers have family from Mississippi – Zinzi's grandparents are from the state as are one of Ryan's grandfathers and an uncle, who inspired him to make the film.
'This is a love letter to our elders, to our recent and relatively distant ancestors, and we are so proud to be here in Clarksdale to share this movie and this moment with you guys,' Zinzi Coogler said ahead of the first screening. 'We heard the call that there isn't a theater for the local community, and said, 'Wait, wait, wait, we will show up.''
Ryan Coogler, an Oakland, California, native, shared that he hadn't visited the Magnolia state before working on the movie.
'Coming here, it blew my mind,' he said of his first visit to the state. 'I got to meet musicians, I got to meet community members, business owners. It really changed me just to come here and do the research.'
Coogler invited the audience to be responsive to the film, and they acquiesced – cheering, laughing and gasping at various times throughout the movie. When the film opened, and 'Clarksdale, Mississippi October 15, 1932' splashed across the screen, the audience was rapturous. Christone 'Kingfish' Ingram, a native of Clarksdale who is featured in the film and attended the screening, likewise received thunderous applause and cheers when he appeared on screen.
After the morning showing, the Cooglers, Göransson, Ohanian and Miles Caton, who had his debut role in the film, and Lawrence 'Boo' Mitchell, Cederic Burnside, Tierinii Jackson and Bobby Rush, all musicians who worked on the film, participated in a question-and-answer session hosted by Clarksdale native Aallyah Wright, of Capital B.
The community has bought into Sinners: A sign outside New Roxy, formerly a Black movie theater and now a music venue, reads: 'Welcome to Clarksdale, Sinners Festival.' Ground Zero, Morgan Freeman's juke joint, offered Sinners-themed drinks: the Smokestack, the Dance with the Devil and the Juke Joint Julep.
'We owe Clarksdale so much, as Mississippians, the world owes Clarksdale and Mississippi as a whole so much for being a staple in the global culture landscape. For me, Sinners was one of my very first experiences of seeing Mississippi in a full and beautiful light on the big screen,' Jasmine Williams, founder of 'Sipp Talk Media and one of the festival's organizers, said in a statement. 'I think this film coming home and being made accessible to the people that inspired it is so important, so people here understand our impact on the world.'
On 29 May, Clarksdale residents had two opportunities to see the film: the 11 am showing and a 5pm showing, both of which were introduced by Coogler himself. Those screenings were part of Clarksdale Cultural Capital, a three-day festival full of panels, music performances and other events featuring people from Clarksdale, across the delta and Mississippi. The festival is sponsored by Warner Brothers, Visit Clarksdale, Capital B, Rootswell, Higher Purpose Hub, Mississippi Humanities, Griot Arts, and other local and regional organizations.
Panels include Coffee With Kinfolk: Our Future of Clarksdale, Building a Blues Economy Rooted in Dignity and Cultural Diversity in the Mississippi Delta: Conversations With Choctaw and Chinese Americans, among others, while musical performances include music inspired by Sinners, held at Morgan Freeman's Ground Zero; a show by Keith Johnson, Muddy Waters' nephew; a Son House recording and jam session; and others.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
33 minutes ago
- Reuters
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
CHICAGO, June 1 (Reuters) - Treating breast cancer patients with AstraZeneca's (AZN.L), opens new tab experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' (NOVN.S), opens new tab Kisqali, Pfizer's (PFE.N), opens new tab Ibrance or Lilly's (LLY.N), opens new tab Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.


Reuters
38 minutes ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.


Times
39 minutes ago
- Times
Robbie Williams review — Robbie does it his way in a five-star stadium triumph
Act now to keep your subscription We've tried to contact you several times as we haven't been able to take payment. You must update your payment details via My Account or by clicking update payment details to keep your subscription.